# FDA recall D-0020-2022

> **American Health Packaging** · Class II · drug recall initiated 2021-09-17.

## Product

GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each with 10 individually blistered doses), Rx only, Manufactured by: Patheon Pharmaceuticals Inc., Cincinnati, OH 45237; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054.  Carton NDC#: 68084-295-21 (Individual Dose NDC: 68084-295-11)

## Reason for recall

Failed Dissolution Specifications: results were above specification.

## Distribution

Nationwide within the USA

## Key facts

- **Recall number:** D-0020-2022
- **Recalling firm:** American Health Packaging
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2021-09-17
- **Report date:** 2021-10-27
- **Termination date:** 2023-06-08

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Columbus, OH, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0020-2022

## Citation

> AI Analytics. FDA recall D-0020-2022. Retrieved 2026-06-09 from https://api.ai-analytics.org/recall/D-0020-2022. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*